Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Under current law, only natural persons can be inventors on a patent. But as AI systems become more sophisticated and domain-specific, questions emerge about whether the creators of such AI might ...

PainChek, EMVision and Clever Culture Systems are among ASX health companies reporting quarterly results today.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Shareholders sued over what they saw as a breach of fiduciary duties by the board of directors regarding the drug Anktiva, ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

Cancer continues to be a substantial global health issue. By customizing prevention, diagnosis, and treatment plans depending on individual patient genetic ...

Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New ...